Effects of insulin-like growth factor 1 in preventing acute coronary syndromes: The PRIME study

Atherosclerosis

Volumn 218, Issue 2, 2011, Pages 464-469

  Ruidavets, J B ^a   Luc, G ^b   Machez, E ^b   Genoux, A L ^c   Kee, F ^d   Arveiler, D ^e   Morange, P ^f   Woodside, J V ^d   Amouyel, P ^b   Evans, A ^g   Ducimetiere P ^d   Bingham, A ^h   Ferrieres J ⁱ   Perret, B ^c  

^a INSERM   (France)

^b UNIV LILLE   (France)

^c Université de Toulouse   (France)

^d QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^e UNIVERSITÉ DE STRASBOURG   (France)

^f TIMONE HOSPITAL   (France)

^g UNIVERSITÉ PARIS SACLAY   (France)

^h HÔPITAL PAUL BROUSSE   (France)

ⁱ TOULOUSE UNIVERSITY HOSPITAL   (France)

Author keywords

Acute coronary syndrome; Apo lipoprotein a i; HDL cholesterol; Insulin like growth factor 1; Myocardial infarction

Indexed keywords

SOMATOMEDIN C;

ACUTE CORONARY SYNDROME; ADULT; ANGINA PECTORIS; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DISEASE COURSE; DISEASE MARKER; ENDOTHELIAL DYSFUNCTION; HEART INFARCTION; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RISK FACTOR; SMOKING; SOCIOECONOMICS; WAIST CIRCUMFERENCE;

ACUTE CORONARY SYNDROME; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; COHORT STUDIES; FOLLOW-UP STUDIES; FRANCE; HUMANS; INFLAMMATION; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NORTHERN IRELAND; PROSPECTIVE STUDIES; QUESTIONNAIRES; RISK FACTORS;

EID: 80053247458     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.05.034     Document Type: Article

References (30)

1. Janssen J.A.M.J.L., Stolk R.P., Pols H.A.P., Grobbee D.E., Lamberts S.W.J. Serum total IGF-I, free IGF-I and IGFBP-1 levels in an elderly population. Relation to cardiovascular risk factors and disease. Arterioscler Thromb Vasc Biol 1998, 18:277-282.
2. Friedrich N., Haring R., Nauck M., et al. Mortality and serum insulin-like growth factor (IGF)-I and IGF binding protein 3 concentrations. J Clin Endocrinol Metab 2009, 94:1732-1739.
3. Schneider H.J., Klotsche J., Saller B., et al. Associations of age-dependent IGF-I SDS with cardiovascular diseases and risk conditions: cross-sectional study in 6773 primary care patients. Eur J Endocrinol 2008, 158:153-161.
4. Hunt K.J., Lukanova A., Rinaldi S., et al. A potential inverse association between insulin-like growth factor I and hypertension in a cross-sectional study. Ann Epidemiol 2006, 16:563-571.
5. Van Bunderen C.C., van Nieuwpoort I.C., van Schoor N.M., Deeg D.J., Lips P., Drent M.L. The association of serum Insulin-like growth factor-I with mortality, cardiovascular disease and cancer in the elderly: a population-based study. J Clin Endocrinol Metab 2010, 95:4616-4624.
6. Brugts M.P., van den Beld A.W., Hofland L.J., et al. Low circulating insulin-like growth factor I bioactivity in elderly men is associated with increased mortality. J Clin Endocrinol Metab 2008, 93:2515-2522.
7. Ducimetière P., Ruidavets J.B., Montaye M., Haas B., Yarnell J. Five-year incidence of angina pectoris and other forms of coronary heart disease in healthy men aged 50-59 in France and Northern Ireland: the Prospective Epidemiological Study of Myocardial Infarction (PRIME) Study. Int J Epidemiol 2001, 30:1057-1062. On behalf of the PRIME Study Group.
8. Colao A., Di Somma C., Cascella T., et al. Relationships between serum IGF1 levels, blood pressure, and glucose tolerance: an observational, exploratory study in 404 subjects. Eur J Endocrinol 2008, 159:389-397.
9. Vaessen N., Heutink P., Janssen J.A., et al. A polymorphism in the gene for IGF-I: functional properties and risk for type-2 diabetes and myocardial infarction. Diabetes 2001, 50:637-642.
10. Candore G., Caruso C., Jirillo E., Magrone T., Vasto S. Low grade inflammation as a common pathogenetic denominator in age-related diseases: novel drug targets for anti-ageing strategies and successful ageing achievement. Curr Pharm Des 2010, 16:584-596.
11. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999, 340:115-126.
12. Sukhanov S., Higashi Y., Shai S.Y., et al. IGF-1 reduces inflammatory responses, suppresses oxidative stress, and decreases atherosclerosis progression in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 2007, 27:2684-2690.
13. De Benedetti F., Alonzi T., Moretta A., et al. Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I. A model for stunted growth in children with chronic inflammation. J Clin Invest 1997, 99:643-650.
14. Rose G.A. The diagnosis of ischaemic heart pain and intermittent claudication in field surveys. Bull World Health Organ 1962, 27:645-658.
15. Prineas R., Crow R., Blackburn H. The Minnesota code manual of electrocardiographic findings 1982, John Wright-PSG, Inc., Littleton, MA.
16. Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 1957, 17:237-246.
17. Yarnell J.W. The PRIME study: classical risk factors do not explain the several fold differences in the risk of coronary heart disease between France and Northern Ireland. Prospective Epidemiological Study of Myocardial Infarction. Q J Med 1998, 91:667-676.
18. Youden W.J. Index for rating diagnostic tests. Cancer 1950, 3:32-35.
19. Kaplan R.C., McGinn A.P., Pollak M.N., et al. Association of total insulin-like growth factor-I, insulin-like growth factor binding protein-1 (IGFBP-1), and IGFBP-3 levels with incident coronary events and ischemic stroke. J Clin Endocrinol Metab 2007, 92:1319-1325.
20. Andreassen M., Kistorp C., Raymond I., et al. Plasma insulin-like growth factor I as predictor of progression and all cause mortality in chronic heart failure. Growth Horm IGF Res 2009, 9:486-490.
21. Tunstall-Pedoe H., Kuulasmaa K., Mahonen M., Tolonen H., Ruokokoski E., Amouyel P. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations. Monitoring trends and determinants in cardiovascular disease. Lancet 1999, 353:1547-1557.
22. Succurro E., Andreozzi F., Sciaqua A., Hribal M.L., Perticone F., Sesti G. Reciprocal association of plasma IGF-1 and interleukin-6 levels with cardio-metabolic risk factors in nondiabetic subjects. Diabetes Care 2008, 31(9):1886-1888.
23. Andrews K.L., Moore X.L., Chin-Dusting J.P. Anti-atherogenic effects of high-density lipoprotein on nitric oxide synthesis in the endothelium. Clin Exp Pharmacol Physiol 2010, 37:736-742.
24. Lowenstein C.J., Cameron S.J. High-density lipoprotein metabolism and endothelial function. Curr Opin Endocrinol Diabetes Obes 2010, 17(2):166-170.
25. Borson-Chazot F., Serusclat A., Kalfallah Y., et al. Decrease in carotid intima-media thickness after one year growth hormone (GH) treatment in adults with GH deficiency. J Clin Endocrinol Metab 1999, 84:1329-1333.
26. Colao A. The GH-IGF-I axis and the cardiovascular system: clinical implications. Clin Endocrinol 2008, 69:347-358.
27. Thum T., Fleissner F., Klink I., et al. Growth hormone treatment improves markers of systemic nitric oxide bioavailability via insulin-like growth factor-I. J Clin Endocrinol Metab 2007, 92:4172-4179.
28. Devin J.K., Young P.P. The effects of growth hormone and insulin-like growth factor-1 on the aging cardiovascular system and its progenitor cells. Curr Opin Investig Drugs 2008, 9:983-992.
29. Empen K., Lorbeer R., Völzke H., et al. Association of serum IGF1 with endothelial function: results from the population-based study of health in Pomerania. Eur J Endocrinol 2010, 163:617-623.
30. Radojkovic C., Genoux A., Pons V., et al. Stimulation of cell surface F1-ATPase activity by apolipoprotein A-I inhibits endothelial cell apoptosis and promotes proliferation. Arterioscler Thromb Vasc Biol 2009, 29:1125-1130.